Categories AlphaGraphs, Earnings, Health Care
Bristol-Myers Q2 earnings, revenue top Street; stock dips on weak guidance
Biopharma company Bristol-Myers Squibb (NYSE: BMY) on Thursday reported higher earnings and revenues for the second quarter, The results also came in above market’s expectations. Meanwhile, the management revised down its full-year earnings guidance, sending the stock lower in the premarket session.
Revenues for the quarter rose 10% to $6.3 billion, surpassing the average analysts’ estimate of $6.11 billion. The top line was boosted by the US segment, which grew 14%. International business revenues rose 5% during the quarter.
The New York-based firm reported adjusted earnings of $1.18 per share, up from last year’s earnings of $1.01 per share and above Wall Street’s prediction. Net earnings attributable to shareholders climbed to f $1.4 billion or $0.87 per share from $373 million or $0.23 per share last year.
Product-wise, melanoma drug Yervoy witnessed a 17% revenue growth, while revenues of Anticoagulant Eliquis moved up 24% year-over-year.
“Through strong commercial execution and financial discipline we are establishing a solid foundation from which we can build the leading biopharma company, well-positioned to address the unmet needs of our patients and create long-term shareholder value,” said CEO Giovanni Caforio.
Melanoma drug Yervoy witnessed a 17% revenue growth, while revenues of Anticoagulant Eliquis moved up 24%
Meanwhile, the company lowered its guidance for full-year unadjusted earnings from $3.84 -$3.94 per share to $3.73- $3.83 per share. It raised the adjusted earnings guidance range from $4.10-$4.20 per share to $4.20-$4.30 per share. Research and development expenses are expected to decline in the low-double digits on an unadjusted basis, and in the mid-single digits on an adjusted basis.
Related: Bristol-Myers Squibb Q4 2018 Earnings Call Transcript
The company said it is on track to complete the acquisition of rival pharma company Celgene. Also, preparations are on for the post-acquisition integration.
Shares of Bristol-Myers dropped early Thursday after closing the previous session higher. The stock lost 18% since the beginning of the year and 24% in the last twelve months.
Most Popular
Can General Motors (GM) navigate the tariff challenge ahead?
General Motors' (NYSE: GM) stock tumbled last week after the Trump administration imposed new tariffs on automobile imports, raising concerns about their potential impact on the company’s production as it
What to look for when Delta Air Lines (DAL) reports its Q1 2025 earnings results
Shares of Delta Air Lines (NYSE: DAL) were down over 1% on Monday. The stock has dropped 28% over the past three months. The airline is scheduled to report its
STZ Earnings Preview: Can Constellation Brands leverage growing beer sales?
Constellation Brands, Inc. (NYSE: STZ) has effectively navigated challenges like cautious consumer spending and declining demand for its wine and spirits brands by capitalizing on the sustained growth in the
